This filing provides a comprehensive description of Replimune Group, Inc.'s registered securities, including its common stock and the terms of its authorized but unissued preferred stock. It details the rights and provisions associated with common stock, such as voting rights, dividend entitlements, and liquidation preferences. The document also outlines the company's authorized capital stock, consisting of 150,000,000 shares of common stock and 10,000,000 shares of undesignated preferred stock. Specific details are provided regarding outstanding pre-funded warrants issued in various offerings and private placements, including their exercise prices and beneficial ownership limitations. The filing also discusses anti-takeover provisions under Delaware law and the company's charter documents, as well as registration rights granted to certain holders of common stock.